11 April 2019
Visiongain has published a new pharma report Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy.
The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018. The changing demographics of the world population, developing infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.
This report profiled the selected companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Celgene and other companies.
The lead analyst commented that "Chemotherapy will continue to be the largest segment for therapy of cancer; however, the huge effort for a breakthrough in cancer treatment will result in the growth of targeted cell therapy as well as immunotherapy segments. High income countries will see more growth in this novel type of therapy when compared to the developing nations due to the high cost of the treatment. Blood cancer market is expected to grow as the number of cases would increase due to non-availability of the perfect treatment options."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In recent years, one area of biopharmaceutical manufacturing that has come under increasing interest is ADC manufacturing.
16 January 2020
In recent years, with the advent of technology, medical practitioners and manufacturers have made huge strides in the wound care market. As one of today’s leading market research and report firms, Visiongain is committed to providing you the most up-to-date information about this exciting industry. That’s why below we’ve collected some of today’s latest products and technologies for your perusal. …
14 January 2020
With the emergence of new health technology and advances in vaccines, manufacturers and key stakeholders can position themselves to generate big returns in the coming years. However, getting ahead of the competition will require having the right tools at your disposal, which is why Visiongain is proud to offer extensive vaccine market forecasts, as well as reports from other verticals …
14 January 2020
New trials from around the world are affecting the global dermatology market on an almost daily basis, providing patients with new drugs and medical practitioners with more innovative treatment technology than ever before. That’s why Visiongain has made it their business to help inform key stakeholders and business owners about the most current changes and emerging trends. Here are a …